カテゴリ： GlobalData, 企業調査, 南アフリカ

Aspen Pharmacare Holdings Ltd (APN)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Aspen Pharmacare Holdings Ltd (APN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8013431
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月28日
◆ページ数：85
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：南アフリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Aspen Pharmacare Holdings Ltd (Aspen) is a specialty and generic pharmaceuticals company that provides pharmaceutical drugs for a range of acute and chronic conditions. The company also manufactures infant nutritionals and consumer healthcare products in selected territories. Its manufacturing capabilities cover a range of product-types including oral solid dose, semi-solids, liquids, steriles, biological, active pharmaceutical ingredients (APIs) and infant nutritionals. The company has presence across Sub-Saharan Africa, Latin America, South East Asia, Eastern Europe, Western Europe and the Commonwealth of Independent States. Aspen is headquartered in Durban, South Africa.

Aspen Pharmacare Holdings Ltd (APN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
Aspen to Acquire Remaining Rights to Anaesthetic Portfolio from Astrazeneca 16
Aspen Japan Acquires Four Ethical Drug Brands from Kyowa Hakko Kirin 17
Aspen Pharmacare Acquires Anaesthesia Portfolio from GlaxoSmithKline 18
Aspen Global to Acquire Rights to Hydroxyprogesterone Caproate Injection form McGuff Pharma 19
Aspen Pharmacare Acquires Southern African Operations and Product Rights from Norgine 20
Aspen Pharmacare Plans to Acquire Infant Nutrition Business 21
Aspen Pharmacare to Acquire Rights to Mono-Embolex from Novartis 22
Aspen Pharma Acquires Infant Nutritional Businesses from Nestle for USD180 Million 23
Aspen Acquires Portfolio of Drugs from Merck for USD600 Million 25
Aspen Pharmacare Completes Acquisition of Thrombosis Brands And Manufacturing Facility from GlaxoSmithKline for USD1.13 Billion 28
Aspen Acquires Active Pharmaceutical Ingredients Business From Merck 30
Aspen Completes Acquisition Of Non-Core Australian Drugs From GlaxoSmithKline For US$257 Million 31
Aspen Pharmacare Completes Acquisition Of Non-Core OTC Brands From GlaxoSmithKline For US$263 Million 33
Aspen Pharmacare Acquires Pharma Division Of Sigma Pharma 35
Partnerships 37
Aspen Pharmacare Holdings to Enter into Research Agreement with Far Eastern Federal University 37
AstraZeneca Enters into Co-Marketing Agreement with Aspen 38
ANI Pharma Enters into Distribution Agreement with Aspen 39
Cardiome Pharma Enters into Co-Marketing Agreement with Aspen Pharma for Brinavess 40
Navamedic Amends Distribution Agreement With Aspen Pharma 41
Cipla Plans To Enters Into Co-Development Agreement With Aspen Pharmacare 42
Licensing Agreements 43
Aspen Pharmacare Australia Enters into Licensing Agreement with Neurim Pharma 43
Aspen Pharma Enters into Licensing Agreement with Starpharma 44
Iroko Pharma Enters into Licensing Agreement with Aspen Pharma for Zorvolex 45
TesoRx Pharma Enters into Licensing Agreement with Aspen Global 46
QRxPharma Exercises Option For Licensing Agreement With Aspen Pharma For Moxduo 47
QRxPharma Enters Into Licensing Agreement With Aspen Pharma For Moxduo 48
Tibotec Pharma Enters Into Licensing Agreement With Aspen Pharmacare For TMC278 49
Equity Offering 50
Aspen Pharmacare Raises USD624 Million in Private Placement of Shares 50
Asset Transactions 52
Endo International Acquires Portfolio of Branded and Generic Products 52
Strides Arcolab Acquires Prescription Products from Aspen Global for USD92 million 53
Strides Arcolab Acquires Generic Pharma Business and Related Assets from Aspen Pharmacare for USD210 Million 54
Aspen Pharmacare to Divest Business Unit to Litha Pharma for USD134 Million 55
Mylan to Acquire Rights to Arixtra Injection from Aspen Global 56
Perrigo Acquires OTC Products From Aspen Global For US$51 Million 57
Lupin Acquires Worldwide Rights To Goanna Brand From Aspen Pharmacare 58
Acquisition 59
GlaxoSmithKline to Acquire 25% Stake in Aspen Japan 59
GlaxoSmithKline Completes Sale Of 6.19% Stake In Aspen Pharmacare For US$696.5 Million 60
Aspen Pharmacare Completes Acquisition Of Remaining 40% Stake In Shelys Africa For US$18.6 Million 62
Aspen Pharmacare Holdings Ltd – Key Competitors 63
Aspen Pharmacare Holdings Ltd – Key Employees 64
Aspen Pharmacare Holdings Ltd – Locations And Subsidiaries 65
Head Office 65
Other Locations & Subsidiaries 65
Joint Venture 67
Recent Developments 68
Financial Announcements 68
Sep 14, 2017: Aspen increases revenue by 16% to R41.2 billion 68
Mar 09, 2017: Aspen: Unaudited interim financial results for the six months ended 31 December 2016 71
Sep 14, 2016: Aspens comparable revenue increases by 12% to R35.4 billion 74
Mar 03, 2016: Aspen’s profit after tax increases by 35% 76
Legal and Regulatory 79
Jun 13, 2017: Aspen: South African Competition Commission Announcement 79
May 15, 2017: Aspen: Opening of European Commission proceedings 80
Apr 24, 2017: Aspen’s response to the reported Competition Commission investigation 81
Government and Public Interest 82
May 15, 2017: Antitrust: Commission opens formal investigation into Aspen Pharma’s pricing practices for cancer medicines 82
Other Significant Developments 84
Mar 01, 2017: Aspen – Trading Statement 84
Appendix 85
Methodology 85
About GlobalData 85
Contact Us 85
Disclaimer 85

List of Tables
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Aspen Pharmacare Holdings Ltd, Deals By Therapy Area, 2011 to YTD 2017 10
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Aspen to Acquire Remaining Rights to Anaesthetic Portfolio from Astrazeneca 16
Aspen Japan Acquires Four Ethical Drug Brands from Kyowa Hakko Kirin 17
Aspen Pharmacare Acquires Anaesthesia Portfolio from GlaxoSmithKline 18
Aspen Global to Acquire Rights to Hydroxyprogesterone Caproate Injection form McGuff Pharma 19
Aspen Pharmacare Acquires Southern African Operations and Product Rights from Norgine 20
Aspen Pharmacare Plans to Acquire Infant Nutrition Business 21
Aspen Pharmacare to Acquire Rights to Mono-Embolex from Novartis 22
Aspen Pharma Acquires Infant Nutritional Businesses from Nestle for USD180 Million 23
Aspen Acquires Portfolio of Drugs from Merck for USD600 Million 25
Aspen Pharmacare Completes Acquisition of Thrombosis Brands And Manufacturing Facility from GlaxoSmithKline for USD1.13 Billion 28
Aspen Acquires Active Pharmaceutical Ingredients Business From Merck 30
Aspen Completes Acquisition Of Non-Core Australian Drugs From GlaxoSmithKline For US$257 Million 31
Aspen Pharmacare Completes Acquisition Of Non-Core OTC Brands From GlaxoSmithKline For US$263 Million 33
Aspen Pharmacare Acquires Pharma Division Of Sigma Pharma 35
Aspen Pharmacare Holdings to Enter into Research Agreement with Far Eastern Federal University 37
AstraZeneca Enters into Co-Marketing Agreement with Aspen 38
ANI Pharma Enters into Distribution Agreement with Aspen 39
Cardiome Pharma Enters into Co-Marketing Agreement with Aspen Pharma for Brinavess 40
Navamedic Amends Distribution Agreement With Aspen Pharma 41
Cipla Plans To Enters Into Co-Development Agreement With Aspen Pharmacare 42
Aspen Pharmacare Australia Enters into Licensing Agreement with Neurim Pharma 43
Aspen Pharma Enters into Licensing Agreement with Starpharma 44
Iroko Pharma Enters into Licensing Agreement with Aspen Pharma for Zorvolex 45
TesoRx Pharma Enters into Licensing Agreement with Aspen Global 46
QRxPharma Exercises Option For Licensing Agreement With Aspen Pharma For Moxduo 47
QRxPharma Enters Into Licensing Agreement With Aspen Pharma For Moxduo 48
Tibotec Pharma Enters Into Licensing Agreement With Aspen Pharmacare For TMC278 49
Aspen Pharmacare Raises USD624 Million in Private Placement of Shares 50
Endo International Acquires Portfolio of Branded and Generic Products 52
Strides Arcolab Acquires Prescription Products from Aspen Global for USD92 million 53
Strides Arcolab Acquires Generic Pharma Business and Related Assets from Aspen Pharmacare for USD210 Million 54
Aspen Pharmacare to Divest Business Unit to Litha Pharma for USD134 Million 55
Mylan to Acquire Rights to Arixtra Injection from Aspen Global 56
Perrigo Acquires OTC Products From Aspen Global For US$51 Million 57
Lupin Acquires Worldwide Rights To Goanna Brand From Aspen Pharmacare 58
GlaxoSmithKline to Acquire 25% Stake in Aspen Japan 59
GlaxoSmithKline Completes Sale Of 6.19% Stake In Aspen Pharmacare For US$696.5 Million 60
Aspen Pharmacare Completes Acquisition Of Remaining 40% Stake In Shelys Africa For US$18.6 Million 62
Aspen Pharmacare Holdings Ltd, Key Competitors 63
Aspen Pharmacare Holdings Ltd, Key Employees 64
Aspen Pharmacare Holdings Ltd, Other Locations 65
Aspen Pharmacare Holdings Ltd, Subsidiaries 65
Aspen Pharmacare Holdings Ltd, Joint Venture 67

★海外企業調査レポート[Aspen Pharmacare Holdings Ltd (APN)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Chromatin Inc：企業のM&A・事業提携・投資動向
    Chromatin Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Chromatin Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Loral Space & Communications Inc. (LORL)：企業の財務・戦略的SWOT分析
    Loral Space & Communications Inc. (LORL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • ViraTherapeutics GmbH：製薬・医療：M&Aディール及び事業提携情報
    Summary ViraTherapeutics GmbH (ViraTherapeutics) is a biotechnology company that develops high potential anti-cancer therapeutics based on cancer-destroying oncolytic viruses. The company provides VSV-GP which is a proprietary oncolytic virus platform, which helps in destroying cancer cells and is u …
  • City Holding Co (CHCO)：企業の財務・戦略的SWOT分析
    City Holding Co (CHCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • NetSol Technologies, Inc. (NTWK)：企業の財務・戦略的SWOT分析
    NetSol Technologies, Inc. (NTWK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Aeon Global Health Corp (ADAT)：医療機器：M&Aディール及び事業提携情報
    Summary Aeon Global Health Corp (Aeon), formerly Authentidate Holding Corp, is a clinical lab and healthcare services organization that offers diagnostic services in cancer genomics, toxicology, pharmacogenomics, and health technology applications. The organization offers clinical laboratory service …
  • Actron Manufacturing, Inc.：企業の戦略・SWOT・財務情報
    Actron Manufacturing, Inc. - Strategy, SWOT and Corporate Finance Report Summary Actron Manufacturing, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Lee Enterprises Inc (LEE)：企業の財務・戦略的SWOT分析
    Lee Enterprises Inc (LEE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • WInco Foods LLC：戦略・SWOT・企業財務分析
    WInco Foods LLC - Strategy, SWOT and Corporate Finance Report Summary WInco Foods LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Tokyo Gas Co., Ltd.：企業の戦略・SWOT・財務分析
    Tokyo Gas Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Tokyo Gas Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Hydrodec Group plc (HYR)：企業の財務・戦略的SWOT分析
    Summary Hydrodec Group Plc (Hydrodec) is an oil and gas company that offers oil refining services. The company produces, markets and distributes transformer oil and naphthenic base oil. It undertakes collection, transportation and processing of used non-PCB and PCB-contaminated naphthenic-based tran …
  • Olvi plc：企業の戦略・SWOT・財務情報
    Olvi plc - Strategy, SWOT and Corporate Finance Report Summary Olvi plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Weis Markets, Inc.：戦略・SWOT・企業財務分析
    Weis Markets, Inc. - Strategy, SWOT and Corporate Finance Report Summary Weis Markets, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Green Cross Cell Corp (031390)：製薬・医療：M&Aディール及び事業提携情報
    Summary Green Cross Cell Corp (Green Cross Cell), a subsidiary of Green Cross Corp, is a provider of immunotherapeutics for the treatment of cancer. The company offers Immuncell-LC, an anti-cancer immune therapeutic that is derived from lymphocytes of cancer patient. It offers cryopreservation of co …
  • Harvard Bioscience Inc (HBIO)：企業の財務・戦略的SWOT分析
    Harvard Bioscience Inc (HBIO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Lukoil Oil Co (LKOH)：企業の財務・戦略的SWOT分析
    Lukoil Oil Co (LKOH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Euskaltel SA (EKT)：企業の財務・戦略的SWOT分析
    Euskaltel SA (EKT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Siegfried Holding AG (SFZN)：企業の財務・戦略的SWOT分析
    Siegfried Holding AG (SFZN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Codexis Inc (CDXS)：製薬・医療：M&Aディール及び事業提携情報
    Summary Codexis Inc (Codexis) is a protein engineering company, which develops proteins for a wide range of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, industrial enzymes and fine chemicals, and enzymes as biotherapeutics and for use in molecular diagno …
  • Crownhaitai Holdings Co Ltd：企業の戦略・SWOT・財務分析
    Crownhaitai Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Crownhaitai Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆